-
BMO Capital Reiterates Silence Therapeutics (SLN) as Top Pick, 'buy the dip'
-
BMO Capital Pounds Table on Silence Therapeutics (SLN), New Top Pick
-
BMO Capital Starts Silence Therapeutics (SLN) at Outperform, 'a key player to watch'

